The Filing Desk

LENZ Therapeutics vs uniQure

LENZ Therapeutics LENZ · uniQure QURE · Biotechnology

LENZ Therapeutics reported revenue of $19 million in fiscal 2025, 1.2 times uniQure's $16 million in fiscal 2025. LENZ Therapeutics had an operating margin of -477.5%, against -1151.4% at uniQure. Free cash flow was −$70 million at LENZ Therapeutics and −$178 million at uniQure.

Side by side

LENZ TherapeuticsuniQure
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$19M$16M
Revenue growth—−40.6%
Revenue growth a year, last 5 years—−15.6%
Gross margin97.8%89.5%
Operating margin−477.5%−1,151.4%
Net margin−430.2%−1,236.0%
Free cash flow−$70M−$178M
Free cash flow margin−366.7%−1,108.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count35.4%18.2%
Last close$3.34$20.23
P/E at the last close——
Insider trades, last 12 monthsbought $365,553, sold $0sold $19.8 million
Piotroski F-score—2 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
LENZ TherapeuticsuniQure
Operating margin
Percent of revenue
LENZ TherapeuticsuniQure
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
LENZ TherapeuticsuniQure

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the LENZ Therapeutics and uniQure pages.